JP2014525926A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014525926A5 JP2014525926A5 JP2014525434A JP2014525434A JP2014525926A5 JP 2014525926 A5 JP2014525926 A5 JP 2014525926A5 JP 2014525434 A JP2014525434 A JP 2014525434A JP 2014525434 A JP2014525434 A JP 2014525434A JP 2014525926 A5 JP2014525926 A5 JP 2014525926A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- region
- combination
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *CCN(CCCl)c1ccc(CCCC(O)=O)cc1 Chemical compound *CCN(CCCl)c1ccc(CCCC(O)=O)cc1 0.000 description 2
- WAMNGGHTLRINPS-UHFFFAOYSA-N CCCN(CCCO1)P1(NCCCl)=O Chemical compound CCCN(CCCO1)P1(NCCCl)=O WAMNGGHTLRINPS-UHFFFAOYSA-N 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N N[C@@H](Cc(cc1)ccc1N(CCCl)CCCl)C(O)=O Chemical compound N[C@@H](Cc(cc1)ccc1N(CCCl)CCCl)C(O)=O SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N O=C(C(N(CCCl)CCCl)=CN1)NC1=O Chemical compound O=C(C(N(CCCl)CCCl)=CN1)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N O=P1(N(CCCl)CCCl)OCCCN1 Chemical compound O=P1(N(CCCl)CCCl)OCCCN1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
Images
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161523861P | 2011-08-16 | 2011-08-16 | |
| US61/523,861 | 2011-08-16 | ||
| EP11177658.9 | 2011-08-16 | ||
| EP11177658 | 2011-08-16 | ||
| US201261647539P | 2012-05-16 | 2012-05-16 | |
| US61/647,539 | 2012-05-16 | ||
| US201261654097P | 2012-06-01 | 2012-06-01 | |
| US61/654,097 | 2012-06-01 | ||
| PCT/EP2012/065906 WO2013024097A1 (en) | 2011-08-16 | 2012-08-14 | Combination therapy with an anti - cd19 antibody and a nitrogen mustard |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014525926A JP2014525926A (ja) | 2014-10-02 |
| JP2014525926A5 true JP2014525926A5 (enExample) | 2015-10-01 |
| JP6184952B2 JP6184952B2 (ja) | 2017-08-23 |
Family
ID=47714801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014525434A Active JP6184952B2 (ja) | 2011-08-16 | 2012-08-14 | 抗ｃｄ１９抗体とナイトロゲンマスタードとの併用療法 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20140255427A1 (enExample) |
| EP (2) | EP4062936A1 (enExample) |
| JP (1) | JP6184952B2 (enExample) |
| KR (3) | KR102115203B1 (enExample) |
| CN (1) | CN103732252B (enExample) |
| AU (1) | AU2012296907B2 (enExample) |
| BR (1) | BR112013033919B1 (enExample) |
| CA (2) | CA3137321A1 (enExample) |
| CY (1) | CY1125122T1 (enExample) |
| DK (1) | DK2744515T3 (enExample) |
| ES (1) | ES2909722T3 (enExample) |
| HR (1) | HRP20220228T1 (enExample) |
| HU (1) | HUE058350T2 (enExample) |
| IL (1) | IL230293B (enExample) |
| LT (1) | LT2744515T (enExample) |
| MX (1) | MX354479B (enExample) |
| PL (1) | PL2744515T3 (enExample) |
| PT (1) | PT2744515T (enExample) |
| RS (1) | RS63238B1 (enExample) |
| RU (1) | RU2625222C2 (enExample) |
| SG (1) | SG10201606785UA (enExample) |
| SI (1) | SI2744515T1 (enExample) |
| SM (1) | SMT202200159T1 (enExample) |
| WO (1) | WO2013024097A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3157553A4 (en) * | 2014-06-16 | 2018-02-28 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (cll) |
| JP6916741B2 (ja) | 2015-05-26 | 2021-08-11 | モルフォシス・アーゲー | 抗ｃｄ１９抗体およびブルトン型チロシンキナーゼ阻害剤の組み合わせ、およびその使用 |
| AU2016311136B2 (en) * | 2015-08-21 | 2022-02-17 | Incyte Corporation | Combinations and uses thereof |
| US20190112380A1 (en) | 2016-03-29 | 2019-04-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| ES2981046T3 (es) * | 2016-05-30 | 2024-10-07 | Incyte Corp | Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes |
| SMT202100317T1 (it) | 2016-06-27 | 2021-07-12 | Morphosys Ag | Formulazioni di anticorpi anti-cd19 |
| WO2018078123A1 (en) | 2016-10-28 | 2018-05-03 | Morphosys Ag | Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof |
| CN110352068A (zh) | 2016-12-02 | 2019-10-18 | 南加利福尼亚大学 | 合成的免疫受体及其使用方法 |
| HUE063119T2 (hu) | 2017-05-31 | 2024-01-28 | Morphosys Ag | Kezelési paradigma anti-CD19 antitest és venetoclax kombinációs kezeléshez |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| US20230357392A1 (en) * | 2021-12-22 | 2023-11-09 | Morphosys Ag | Treatment Paradigm for an Anti-CD19 Antibody Therapy |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| CA2326389C (en) * | 1998-04-21 | 2007-01-23 | Micromet Gesellschaft Fur Biomedizinische Forschung Mbh | Novel cd19xcd3 specific polypeptides and uses thereof |
| IL146005A0 (en) * | 1999-05-07 | 2002-07-25 | Genentech Inc | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
| WO2002022212A2 (en) | 2000-09-18 | 2002-03-21 | Idec Pharmaceuticals Corporation | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| JP4733635B2 (ja) | 2003-07-31 | 2011-07-27 | イミューノメディクス、インコーポレイテッド | 抗ｃｄ１９抗体 |
| EP1814544A4 (en) | 2004-11-05 | 2009-12-02 | Cephalon Inc | CANCER TREATMENTS |
| WO2007002223A2 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| AU2006332155B2 (en) * | 2005-12-30 | 2013-01-10 | Cancer Research Technology Limited | Anti-CD19 antibodies with reduced immunogenicity |
| RS53263B (sr) * | 2006-08-14 | 2014-08-29 | Xencor Inc. | Optimizovana antitela usmerena na cd19 |
| US8323653B2 (en) | 2006-09-08 | 2012-12-04 | Medimmune, Llc | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| CA2693053C (en) | 2007-05-30 | 2021-01-05 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| CN101903403B (zh) | 2007-10-19 | 2016-03-16 | 西雅图基因公司 | Cd19结合剂及其应用 |
| EA201170940A1 (ru) * | 2009-01-16 | 2012-02-28 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела |
| CA2753158A1 (en) | 2009-02-23 | 2010-08-26 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to cd19 and their uses |
| EP2445530B1 (en) | 2009-06-24 | 2016-09-07 | The Feinstein Institute for Medical Research | Method for treating chronic lymphocytic leukemia |
| TWI409079B (zh) * | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法 |
| BR112012003066A2 (pt) * | 2009-08-14 | 2016-11-16 | Roche Glycart Ag | uso de um anticorpo anti-cd20 defucosilado e composição compreendendo um anticorpo anti-cd20 defucosilado |
| WO2011057222A1 (en) * | 2009-11-06 | 2011-05-12 | Infinity Pharmaceuticals, Inc. | Oral formulations of a hedgehog pathway inhibitor |
-
2012
- 2012-08-14 SG SG10201606785UA patent/SG10201606785UA/en unknown
- 2012-08-14 HU HUE12747923A patent/HUE058350T2/hu unknown
- 2012-08-14 MX MX2013014933A patent/MX354479B/es active IP Right Grant
- 2012-08-14 KR KR1020197026462A patent/KR102115203B1/ko active Active
- 2012-08-14 US US14/126,928 patent/US20140255427A1/en not_active Abandoned
- 2012-08-14 SM SM20220159T patent/SMT202200159T1/it unknown
- 2012-08-14 HR HRP20220228TT patent/HRP20220228T1/hr unknown
- 2012-08-14 RU RU2014103492A patent/RU2625222C2/ru active
- 2012-08-14 AU AU2012296907A patent/AU2012296907B2/en active Active
- 2012-08-14 KR KR1020147006936A patent/KR20140064873A/ko not_active Ceased
- 2012-08-14 PT PT127479236T patent/PT2744515T/pt unknown
- 2012-08-14 CA CA3137321A patent/CA3137321A1/en active Pending
- 2012-08-14 RS RS20220412A patent/RS63238B1/sr unknown
- 2012-08-14 BR BR112013033919-5A patent/BR112013033919B1/pt active IP Right Grant
- 2012-08-14 WO PCT/EP2012/065906 patent/WO2013024097A1/en not_active Ceased
- 2012-08-14 DK DK12747923.6T patent/DK2744515T3/da active
- 2012-08-14 KR KR1020207014299A patent/KR20200058583A/ko not_active Withdrawn
- 2012-08-14 SI SI201231989T patent/SI2744515T1/sl unknown
- 2012-08-14 ES ES12747923T patent/ES2909722T3/es active Active
- 2012-08-14 LT LTEPPCT/EP2012/065906T patent/LT2744515T/lt unknown
- 2012-08-14 PL PL12747923T patent/PL2744515T3/pl unknown
- 2012-08-14 CN CN201280036571.XA patent/CN103732252B/zh active Active
- 2012-08-14 CA CA2841875A patent/CA2841875C/en active Active
- 2012-08-14 EP EP22155572.5A patent/EP4062936A1/en active Pending
- 2012-08-14 JP JP2014525434A patent/JP6184952B2/ja active Active
- 2012-08-14 EP EP12747923.6A patent/EP2744515B1/en active Active
-
2014
- 2014-01-02 IL IL230293A patent/IL230293B/en active IP Right Grant
-
2020
- 2020-04-03 US US16/839,777 patent/US20200353077A1/en not_active Abandoned
-
2022
- 2022-04-18 CY CY20221100289T patent/CY1125122T1/el unknown
-
2024
- 2024-01-12 US US18/411,350 patent/US20240366756A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022202796B2 (en) | Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof | |
| US20240366756A1 (en) | Combinations and uses thereof | |
| JP6114273B2 (ja) | 抗−ｃｄ１９抗体とプリン類似体の併用治療 | |
| JP2025131697A (ja) | 組み合わせおよびその使用 | |
| JP2014525925A5 (enExample) | ||
| JP7094950B2 (ja) | 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用 | |
| AU2012296907A1 (en) | Combination therapy with an anti - CD19 antibody and a nitrogen mustard | |
| HK40081594A (en) | Combination therapy with an anti-cd19 antibody and a nitrogen mustard | |
| NZ617770B2 (en) | Combination therapy with an anti - cd19 antibody and a nitrogen mustard |